The 2nd HPD report - Health Policy Monitor

Public Visibility
Impact
Transferability
Sources and further reading:
“Cohesion and Quality of the National Health System Act”
(Act 16/2003, May 28).
Colegio Oficial de Farmacéuticos de Valencia. “Repercusión
sobre la economía de la oficina de farmacia de la Orden
Ministerial que desarrolla la disposición final tercera
de la Ley de Cohesión y Calidad del Sistema Nacional de
Salud.” (Effects on the pharmacy office of the recent
changes introduced in the reference pricing system by the
Cohesion and Quality of the National Health System Act).
October 2003.
Economic and Social Council (CES). “Dictamen sobre el
proyecto de orden del Ministerio de Sanidad y Consumo,
por la que se determinan los nuevos conjuntos de presentaciones
y de especialidades farmacéuticas y se aprueban
los correspondientes precios de referencia.” (Report on the
mandatory project issued by the Minister of Health and
Consumption establishing new groups of medicines and
their reference pricing levels). Madrid, 17 September 2003.
Minister of Health and Consumption. “Orden 2958/2003.”
October 23, 2003. (Established new groups of medicines
and their referencing pricing levels.)
Raimundez, G. “Precios de referencia: la crónica de una
muerte anunciada para el genérico.” (Reference pricing:
The chronicle of a death foretold for generics). Revista Española
de Economía de la Salud, May–June 2003, 158–161.
Republic of Korea: Separation of drug prescribing and dispensing
Until the year 2000, physicians as well as pharmacists in South
Korea could prescribe and dispense drugs. Both professions were
inclined to prescribe and deliver large amounts of pharmaceuticals
and expensive drugs, as they purchase drugs at much lower
prices than the reimbursement prices. This contributed to a considerable
part of their income and thereby maximized their profits.
It also increased the public expenditure on pharmaceuticals
and created a serious potential for drug misuse.
64